| 1 |
Recommendations and rationale for the treatment of pelvic inflammatory disease |
|
|
| Jaiyeoba, O., Lazenby, G., Soper, D.E. |
|
| Expert Review of Anti-Infective Therapy. 2011; 9(1): 61-70 |
|
| [Pubmed] [Google Scholar] |
|
| 2 |
UPLC method for simultaneous separation and estimation of secnidazole, fluconazole and azithromycin in pharmaceutical dosage forms |
|
|
| Yanamandra, R., Chaudhary, A., Bandaru, S.R., Patro, B., Murthy, Y.L.N., Ramaiah, P.A., Sastry, C.S.P. |
|
| E-Journal of Chemistry. 2010; 7(sup 1): s363-s371 |
|
| [Pubmed] [Google Scholar] |
|
| 3 |
Pelvic inflammatory disease |
|
|
| Soper, D.E. |
|
| Obstetrics and Gynecology. 2010; 116(2): 419-428 |
|
| [Pubmed] [Google Scholar] |
|
| 4 |
Syndromic management of pelvic inflammatory disease |
|
|
| Gilani, S. |
|
| Journal of Medical Sciences. 2010; 18(1): 8-10 |
|
| [Pubmed] [Google Scholar] |
|
| 5 |
Tinidazole: A classical anaerobical drug with multiple potential uses nowadays | [Tinidazol: Un anaerobicida clásico con múltiples usos potenciales en la actualidad] |
|
|
| Granizo Martinez, J.J., Rodicio, Ma.P., Manso, F.J., Giménez, Ma.J. |
|
| Revista Espanola de Quimioterapia. 2009; 22(2): 106-114 |
|
| [Pubmed] [Google Scholar] |
|
| 6 |
Treatment strategies for pelvic inflammatory disease |
|
|
| Sweet, R.L. |
|
| Expert Opinion on Pharmacotherapy. 2009; 10(5): 823-837 |
|
| [Pubmed] [Google Scholar] |
|
| 7 |
Pelvic Inflammatory Disease and Tubo-ovarian Abscess |
|
|
| Lareau, S.M., Beigi, R.H. |
|
| Infectious Disease Clinics of North America. 2008; 22(4): 693-708 |
|
| [Pubmed] [Google Scholar] |
|
| 8 |
Diagnosis and treatment of pelvic inflammatory disease |
|
|
| Haggerty, C.L., Ness, R.B. |
|
| Womenæs Health. 2008; 4(4): 383-397 |
|
| [Pubmed] [Google Scholar] |
|
| 9 |
Do short-term markers of treatment efficacy predict long-term sequelae of pelvic inflammatory disease? |
|
|
| Trautmann, G.M., Kip, K.E., Richter, H.E., Soper, D.E., Peipert, J.F., Nelson, D.B., Trout, W., (...), Ness, R.B. |
|
| American Journal of Obstetrics and Gynecology. 2008; 198(1): 30-e1-30-e7 |
|
| [Pubmed] [Google Scholar] |
|
| 10 |
Newest approaches to treatment of pelvic inflammatory disease: A review of recent randomized clinical trials |
|
|
| Haggerty, C.L., Ness, R.B. |
|
| Clinical Infectious Diseases. 2007; 44(7): 953-960 |
|
| [Pubmed] [Google Scholar] |
|
| 11 |
Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: A randomized controlled trial |
|
|
| Savaris, R.F., Teixeira, L.M., Torres, T.G., Edelweiss, M.I.A., Moncada, J., Schachter, J. |
|
| Obstetrics and Gynecology. 2007; 110(1): 53-60 |
|
| [Pubmed] [Google Scholar] |
|
| 12 |
Antibiotic therapy for acute pelvic inflammatory disease: The 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines |
|
|
| Walker, C.K., Wiesenfeld, H.C. |
|
| Clinical Infectious Diseases. 2007; 44 (Suppl 3): S111-S122 |
|
| [Pubmed] [Google Scholar] |
|
| 13 |
Comparison of ofloxacin & ornidazole with probiotic versus doxycycline & metronidazole for the outpatient treatment of pelvic inflammatory disease |
|
|
| Sharma, J.B., Chanana, C., Kumar, S., Roy, K., Malhotra, N. |
|
| JK Science. 2007; 9(2): 66-69 |
|
| [Pubmed] [Google Scholar] |
|
| 14 |
Efficacies of caspofungin and a combination of caspofungin and meropenem in the treatment of murine disseminated candidiasis |
|
|
| Ozcan, S.K., Budak, F., Willke, A., Filiz, S., Costur, P., Dalcik, H. |
|
| APMIS. 2006; 114(12): 829-836 |
|
| [Pubmed] [Google Scholar] |
|
| 15 |
Epidemiology, pathogenesis and treatment of pelvic inflammatory disease |
|
|
| Haggerty, C.L., Ness, R.B. |
|
| Expert Review of Anti-Infective Therapy. 2006; 4(2): 235-247 |
|
| [Pubmed] [Google Scholar] |
|
| 16 |
Comparative efficacy of two regimens in syndromic management of lower genital infections |
|
|
| Sharma, J.B., Mittal, S., Raina, U., Chanana, C. |
|
| Archives of Gynecology and Obstetrics. 2006; 273(4): 232-235 |
|
| [Pubmed] [Google Scholar] |
|
| 17 |
Review on the outpatient treatment for pelvic inflammatory disease, what is the best for Hong Kong? |
|
|
| Kung, S.W., Ng, M.H. |
|
| Hong Kong Journal of Emergency Medicine. 2005; 12(3): 162-167 |
|
| [Pubmed] [Google Scholar] |
|
| 18 |
Tinidazole: A nitroimidazole antiprotozoal agent |
|
|
| Fung, H.B., Doan, T.-L. |
|
| Clinical Therapeutics. 2005; 27(12): 1859-1884 |
|
| [Pubmed] [Google Scholar] |
|
| 19 |
Tinidazole: From protozoa to Helicobacter pylori - The past, present and future of a nitroimidazole with peculiarities |
|
|
| Manes, G., Balzano, A. |
|
| Expert Review of Anti-Infective Therapy. 2004; 2(5): 695-705 |
|
| [Pubmed] [Google Scholar] |
|
